Issues related to drug pricing and reimbursement for prescription drugs; Issues related to pharmaceutical supply chain and health appropriations; Issues related to Medicare Part D policies, including non-interference and rebate policy issues; Issues related to women's health; Issues related to oncology; Issues related to ophthalmology.
2025 · 2nd Quarter (Apr 1 - June 30)
TIBER CREEK GROUP ON BEHALF OF ASTELLAS PHARMA US, INC.
Filed by B HALL STRATEGIES, LLC.
Open official filingSource-reported fields
Filing overview
- Type
- Registration
- Posted
- Jul 15, 2025
- Income
- Not reported
- Expenses
- Not reported
- Registrant
- B HALL STRATEGIES, LLC
- Filing UUID
- d1329de4-8c24-48f7-a016-5ff330bc53e7
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to drug pricing and reimbursement for prescription drugs; Issues related to pharmaceutical supply chain and health appropriations; Issues related to Medicare Part D policies, including non-interference and rebate policy issues; Issues related to women's health; Issues related to oncology; Issues related to ophthalmology.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.